Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05833022 · ClinicalTrials.gov registry record

Patient Characteristics and Treatment Patterns From Early Crizanlizumab Use in Real-world Setting: Preliminary Analysis From Select Sickle Cell Centers

A clinical trial of Sickle Cell Disease, sponsored by Novartis Pharmaceuticals.

Completed
Registry status
297
Enrollment target
11
Study locations

NCT05833022 is a study of Sickle Cell Disease that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 297 participants, roughly in line with the 291-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target. The trial reports 11 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05833022, a study of Sickle Cell Disease, has completed, sponsored by Novartis Pharmaceuticals.

COMPLETED
Registry status
297 participants
Enrollment target
11
Study locations

Study Summary

This was a retrospective cohort study using secondary data from member sites of the National Alliance of Sickle Cell Centers (NASCC) with at least five patients who initiated crizanlizumab. Patients who were prescribed crizanlizumab were included in the cohort.

Conditions Studied

Sickle Cell Disease

Study Locations (11)

Ohio

  • University Hospital at Cleveland Medical Center - Cleveland
  • Ohio State University - Columbus

Alabama

  • University of Alabama Birmingham - Birmingham

Delaware

  • Cristiana Care - Wilmington

Florida

  • All Children's Hospital - St. Petersburg

Maryland

  • Johns Hopkins University - Baltimore

Missouri

  • Washington University of St. Louis - St Louis

New Jersey

  • Beth Israel Hospital - East Hanover

New York

  • Montefiore - New York

Trial Details

FieldValue
Enrollment Target 297 participants
Start Date 2021-07-30
Est. Completion 2022-04-18

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05833022

The ClinicalTrials.gov registry entry for NCT05833022 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 297 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 291-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 0 interventions.

NCT05833022 reports 11 study locations spanning 10 distinct geographic areas - top geographies include Ohio, Alabama, Delaware.

Frequently Asked Questions

What is clinical trial NCT05833022 about?

NCT05833022 is a clinical study titled "Patient Characteristics and Treatment Patterns From Early Crizanlizumab Use in Real-world Setting: Preliminary Analysis From Select Sickle Cell Centers". This was a retrospective cohort study using secondary data from member sites of the National Alliance of Sickle Cell Centers (NASCC) with at least five patients who initiated crizanlizumab. Patients who were prescribed crizanlizumab were included in the cohort.

What is the current status of trial NCT05833022?

This trial is currently completed. The enrollment target is 297 participants. The study started on 2021-07-30. Estimated completion is 2022-04-18.

What conditions does trial NCT05833022 study?

This clinical trial studies the following conditions: Sickle Cell Disease.

Who is sponsoring clinical trial NCT05833022?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05833022 being conducted?

This trial has 11 study locations across Alabama, Delaware, Florida, Maryland, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sickle Cell Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Sickle Cell Disease

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.